Ida Marie Heeholm Sønderstrup1, Sune Boris Nygård2, Tim Svenstrup Poulsen3, Dorte Linnemann4, Jan Stenvang5, Hans Jørgen Nielsen6, Jiri Bartek7, Nils Brünner8, Peter Nørgaard9, Lene Riis10. 1. Department of Pathology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: idms@regionsjaelland.dk. 2. Section of Molecular Disease Biology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, Grønnegårdsvej 15, DK-1870 Frederiksberg C, Denmark. Electronic address: whp661@alumni.ku.dk. 3. Department of Pathology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: tim.svenstrup.poulsen@regionh.dk. 4. Department of Pathology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: dorte.linnemann@regionh.dk. 5. Section of Molecular Disease Biology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, Grønnegårdsvej 15, DK-1870 Frederiksberg C, Denmark. Electronic address: stenvang@sund.ku.dk. 6. Department of Surgical Gastroenterology, Copenhagen University Hospital, Hvidovre, Kettegårds Allé 30, DK-2650 Hvidovre, Denmark. Electronic address: hans.joergen.nielsen@regionh.dk. 7. Danish Cancer Research Center, The Danish Cancer Society, Strandboulevarden 49, DK-2100 Copenhagen Ø, Denmark; Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University, Olomouc, Tr Svobody 8, 771 26 Olomouc, Czech Republic. Electronic address: jb@cancer.dk. 8. Section of Molecular Disease Biology, Department of Veterinary Disease Biology, Faculty of Health and Medical Sciences, Grønnegårdsvej 15, DK-1870 Frederiksberg C, Denmark. Electronic address: nbr@sund.ku.dk. 9. Department of Pathology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: peter.h.noergaard@regionh.dk. 10. Department of Pathology, Herlev Hospital, Herlev Ringvej 75, DK-2730 Herlev, Denmark. Electronic address: lene.buhl.riis@regionh.dk.
Abstract
INTRODUCTION: Topoisomerase 1 (TOP1) and 2A (TOP2A) are potential predictive biomarkers for irinotecan and anthracycline treatment, respectively, in colorectal cancer (CRC), and we have recently reported a high frequency of gene gain of the TOP1 and TOP2A genes in CRC. Furthermore, Mismatch Repair (MMR) subtypes of CRC have been associated with benefit from adjuvant chemotherapy of primary CRC. Given the involvement of the topoisomerase enzymes in DNA replication and repair, we raised the hypothesis that an association may exist between TOP gene copy numbers and MMR proficiency/deficiency in CRC. MATERIAL AND METHODS: Test cohort: FISH analysis with an in-house TOP1/CEN20 probe mix and a commercially available TOP2A/CEN17 (Dako, Glostrup, Denmark) probe mix was performed on archival formalin fixed paraffin embedded (FFPE) tissue samples from 18 patients with proficient MMR (pMMR) CRC and 18 patients with deficient MMR (dMMR) CRC. TOP1 and TOP2A gene copy numbers and their ratios per nucleus were correlated with MMR status using the Mann-Whitney test. Validation cohort: FFPE samples from 154 patients with primary stage III CRC (originally included in the RANX05 study) were classified according to MMR status by immunohistochemical analysis using validated antibodies for MLH1, MLH2, MSH6 and PMS2, and information on TOP1, CEN20, TOP2A and CEN17 status was previously published for this cohort. RESULTS: The observed TOP1 gene copy numbers in the 36 CRC test cohort were significantly greater (p < 0.01) in the pMMR subgroup (mean: 3.84, SD: 2.03) than in the dMMR subgroup (mean: 1.50, SD: 0.12). Similarly, the TOP2A copy numbers were significantly greater (p < 0.01) in the pMMR subgroup (mean: 1.99, SD: 0.52) than in the dMMR subgroup (mean: 1.52, SD: 0.10). These findings were confirmed in the validation cohort, where in the pMMR subgroup 51% had ≥2 extra TOP1 copies per cell, while all tumors classified as dMMR had diploid TOP1 status and mean TOP2A copy numbers were 2.30 (SD: 1.36) and 1.80 (SD: 0.31) (p = 0.01) in the pMMR subgroup vs. dMMR subgroup, respectively. DISCUSSION AND CONCLUSION: Our results show that TOP1 and TOP2A gene copy numbers are increased in the pMMR subgroup. We propose that this preference may reflect a selective pressure to gain and/or maintain the gained extra copies of topoisomerase genes whose products are required to cope with high replication stress present in the pMMR tumors, thereby providing a survival advantage selectively in pMMR tumors. Future studies should test this concept and explore potential differences between pMMR and dMMR tumors in response to Top1 and Top2 inhibitors.
INTRODUCTION: Topoisomerase 1 (TOP1) and 2A (TOP2A) are potential predictive biomarkers for irinotecan and anthracycline treatment, respectively, in colorectal cancer (CRC), and we have recently reported a high frequency of gene gain of the TOP1 and TOP2A genes in CRC. Furthermore, Mismatch Repair (MMR) subtypes of CRC have been associated with benefit from adjuvant chemotherapy of primary CRC. Given the involvement of the topoisomerase enzymes in DNA replication and repair, we raised the hypothesis that an association may exist between TOP gene copy numbers and MMR proficiency/deficiency in CRC. MATERIAL AND METHODS: Test cohort: FISH analysis with an in-house TOP1/CEN20 probe mix and a commercially available TOP2A/CEN17 (Dako, Glostrup, Denmark) probe mix was performed on archival formalin fixed paraffin embedded (FFPE) tissue samples from 18 patients with proficient MMR (pMMR) CRC and 18 patients with deficient MMR (dMMR) CRC. TOP1 and TOP2A gene copy numbers and their ratios per nucleus were correlated with MMR status using the Mann-Whitney test. Validation cohort: FFPE samples from 154 patients with primary stage III CRC (originally included in the RANX05 study) were classified according to MMR status by immunohistochemical analysis using validated antibodies for MLH1, MLH2, MSH6 and PMS2, and information on TOP1, CEN20, TOP2A and CEN17 status was previously published for this cohort. RESULTS: The observed TOP1 gene copy numbers in the 36 CRC test cohort were significantly greater (p < 0.01) in the pMMR subgroup (mean: 3.84, SD: 2.03) than in the dMMR subgroup (mean: 1.50, SD: 0.12). Similarly, the TOP2A copy numbers were significantly greater (p < 0.01) in the pMMR subgroup (mean: 1.99, SD: 0.52) than in the dMMR subgroup (mean: 1.52, SD: 0.10). These findings were confirmed in the validation cohort, where in the pMMR subgroup 51% had ≥2 extra TOP1 copies per cell, while all tumors classified as dMMR had diploid TOP1 status and mean TOP2A copy numbers were 2.30 (SD: 1.36) and 1.80 (SD: 0.31) (p = 0.01) in the pMMR subgroup vs. dMMR subgroup, respectively. DISCUSSION AND CONCLUSION: Our results show that TOP1 and TOP2A gene copy numbers are increased in the pMMR subgroup. We propose that this preference may reflect a selective pressure to gain and/or maintain the gained extra copies of topoisomerase genes whose products are required to cope with high replication stress present in the pMMR tumors, thereby providing a survival advantage selectively in pMMR tumors. Future studies should test this concept and explore potential differences between pMMR and dMMRtumors in response to Top1 and Top2 inhibitors.
Authors: Maria Unni Rømer; Sune Boris Nygård; Ib Jarle Christensen; Signe Lykke Nielsen; Kirsten Vang Nielsen; Sven Müller; David Hersi Smith; Ben Vainer; Hans Jørgen Nielsen; Nils Brünner Journal: Mol Oncol Date: 2012-10-11 Impact factor: 6.603
Authors: Ida Marie Heeholm Sønderstrup; Sune Boris Nygård; Tim Svenstrup Poulsen; Dorte Linnemann; Jan Stenvang; Hans Jørgen Nielsen; Jiri Bartek; Nils Brünner; Peter Nørgaard; Lene Riis Journal: Mol Oncol Date: 2015-03-04 Impact factor: 6.603
Authors: Line S Tarpgaard; Camilla Qvortrup; Sune B Nygård; Signe L Nielsen; Diana R Andersen; Niels Frank Jensen; Jan Stenvang; Sönke Detlefsen; Nils Brünner; Per Pfeiffer Journal: BMC Cancer Date: 2016-02-11 Impact factor: 4.430
Authors: Vito Cucchiara; Joy C Yang; Vincenzo Mirone; Allen C Gao; Michael G Rosenfeld; Christopher P Evans Journal: Cancers (Basel) Date: 2017-01-16 Impact factor: 6.639
Authors: Ryan C Fields; Christopher A Maher; Jessica M Silva-Fisher; Ha X Dang; Nicole M White; Matthew S Strand; Bradley A Krasnick; Emily B Rozycki; Gejae G L Jeffers; Julie G Grossman; Maureen K Highkin; Cynthia Tang; Christopher R Cabanski; Abdallah Eteleeb; Jacqueline Mudd; S Peter Goedegebuure; Jingqin Luo; Elaine R Mardis; Richard K Wilson; Timothy J Ley; Albert C Lockhart Journal: Nat Commun Date: 2020-05-01 Impact factor: 14.919
Authors: Jan Stenvang; Eva Budinská; Eric van Cutsem; Fred Bosman; Vlad Popovici; Nils Brünner Journal: Cancers (Basel) Date: 2020-04-15 Impact factor: 6.639